Filtered By:
Specialty: Hematology
Cancer: Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 99 results found since Jan 2013.

Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach
ConclusionNo signal of DDIs between DOACs and antineoplastic agents was detected, except for DOAC-neratinib. Most DDIs between DOACs and antineoplastic agents may not be clinically relevant. The DDIs between DOACs and neratinib should be further examined in future research.
Source: Journal of Thrombosis and Thrombolysis - August 10, 2023 Category: Hematology Source Type: research

Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment
Semin Thromb Hemost DOI: 10.1055/s-0043-1771270Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke in cancer patients. Novel biomarkers, including coagulation, platelet and endothelial markers, cell-free DNA, and extracellular vesicles are being investigated for their potentia...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2023 Category: Hematology Authors: Costamagna, Gianluca Navi, Babak B. Beyeler, Morin Hottinger, Andreas F. Alberio, Lorenzo Michel, Patrik Tags: Review Article Source Type: research

Cerebral infarction and in-hospital mortality for patients admitted to hospital with intracardiac thrombus: insights from the National Inpatient Sample
Abstract The factors associated with cerebral infarction and mortality in patients hospitalized with intracardiac thrombus are unknown. A retrospective cohort study was undertaken of nationally representative hospital admissions in the National Inpatient Sample with a diagnosis of intracardiac thrombus between 2016 to 2019. Multiple logistic regressions were used to define factors associated with cerebral infarction and in-hospital mortality. There were a total of 175,370 admissions for patients with intracardiac thrombus and 10.1% patients had cerebral infarction (n  = 17,675). Intracardiac thrombus represented 4.4%...
Source: Journal of Thrombosis and Thrombolysis - June 5, 2023 Category: Hematology Source Type: research

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer
AbstractPurpose of ReviewThis review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).Recent FindingsThe MPN natural history is driven by uncontrolled clonal myeloproliferation sustained by acquired somatic mutations in driver (JAK2, CALR, and MPL) and non-driver genes, involving epigenetic (e.g., TET2, DNMT3A) regulators, chromatin regulator genes (e.g., ASXL1, EZH2), and splicing machinery ...
Source: Current Hematologic Malignancy Reports - May 24, 2023 Category: Hematology Source Type: research

Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years
Semin Thromb Hemost DOI: 10.1055/s-0043-1769013Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially...
Source: Seminars in Thrombosis and Hemostasis - May 18, 2023 Category: Hematology Authors: Tufano, Antonella Brenner, Benjamin Tags: Review Article Source Type: research

Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research

Stroke mortality in cancer survivors: A population-based study in Japan
The association between cancer survivors and stroke deaths remains unclear. We aimed to evaluate the risk of fatal stroke in patients with cancer.
Source: Thrombosis Research - January 9, 2023 Category: Hematology Authors: Yasufumi Gon, Ling Zha, Tsutomu Sasaki, Toshitaka Morishima, Yuko Ohno, Hideki Mochizuki, Tomotaka Sobue, Isao Miyashiro Source Type: research

Impact of stroke on survival in patients with cancer
Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), are significant concerns for patients with cancer as they can interrupt or delay essential cancer treatments and worsen outcomes [1]. Previous studies have suggested that VTE is associated with an increased risk of mortality in patients with cancer [2 –5]. Meanwhile, few studies have investigated the relationship between ATE and outcomes in patients with cancer. Grilz et al. assessed the effect of ATE on 2-year survival in such patients and reported that ATE was associated with a 3.2-fold increased risk of all-cause mortality [6].
Source: Thrombosis Research - January 6, 2023 Category: Hematology Authors: Yasufumi Gon, Tsutomu Sasaki, Tomohiro Kawano, Shuhei Okazaki, Kenichi Todo, Toshihiro Takeda, Yasushi Matsumura, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research

Cancer and stroke: What do we know and where do we go?
Cancer is an increasingly recognized cause for ischemic stroke, with recent acknowledgement of cancer-related stroke as an emerging stroke subtype with unique pathophysiologic mechanisms. In addition, cancer-related stroke may differ from stroke in the general population as cancer patients may not receive guideline-recommended stroke care, and the occurrence of stroke may also preclude patients from receiving optimal cancer treatments. Due to the high degree of morbidity and mortality associated with both conditions, understanding the relationship between stroke and cancer is crucial.
Source: Thrombosis Research - September 16, 2022 Category: Hematology Authors: Ronda Lun, Deborah Siegal, Tim Ramsay, Dar Dowlatshahi Source Type: research

Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis
CONCLUSIONS: This study demonstrates that clot-targeted MH can enhance the thrombolysis of contracted human blood clots and can be safely applied to enhance the timeframe in which thrombolysis is effective.PMID:35950914 | DOI:10.1111/jth.15846
Source: Thrombosis and Haemostasis - August 11, 2022 Category: Hematology Authors: David Cabrera Maneea Eizadi Sharifabad Jacob A Ranjbar Neil D Telling Alan G S Harper Source Type: research

Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
In conclusion, this systematic review informs on several potential risk factors and predictors for VTE in people with ischemic stroke. To improve risk stratification and guide development of risk prediction models, further confirmation is needed, as there were few high-quality studies on each factor.PMID:35815351 | DOI:10.1111/jth.15813
Source: Thrombosis and Haemostasis - July 11, 2022 Category: Hematology Authors: Birgitte G T øndel V ânia M Morelli John-Bjarne Hansen Sigrid K Braekkan Source Type: research